Research Analysts Issue Forecasts for FULC FY2024 Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Stock analysts at HC Wainwright raised their FY2024 EPS estimates for Fulcrum Therapeutics in a research report issued to clients and investors on Thursday, November 14th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.12) per share for the year, up from their prior forecast of ($0.15). HC Wainwright has a “Neutral” rating and a $4.00 price target on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Fulcrum Therapeutics’ Q4 2024 earnings at ($0.23) EPS, Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.81) EPS, FY2026 earnings at ($1.00) EPS, FY2027 earnings at ($0.99) EPS and FY2028 earnings at ($0.84) EPS.

Several other equities research analysts also recently commented on the stock. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday. Leerink Partnrs cut Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. Stifel Nicolaus downgraded Fulcrum Therapeutics from a “buy” rating to a “hold” rating and dropped their price target for the company from $22.00 to $3.00 in a research note on Thursday, September 12th. Leerink Partners restated a “market perform” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, September 12th. Finally, Bank of America lowered Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and dropped their target price for the company from $10.00 to $2.00 in a research report on Thursday, September 12th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Fulcrum Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $9.33.

Fulcrum Therapeutics Trading Down 9.3 %

NASDAQ FULC opened at $3.01 on Monday. The firm’s fifty day simple moving average is $3.75 and its two-hundred day simple moving average is $6.47. The firm has a market capitalization of $162.36 million, a P/E ratio of -9.69 and a beta of 2.24. Fulcrum Therapeutics has a 12-month low of $2.87 and a 12-month high of $13.70.

Institutional Trading of Fulcrum Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FULC. Braidwell LP purchased a new stake in shares of Fulcrum Therapeutics during the 3rd quarter worth about $3,817,000. State Street Corp raised its holdings in Fulcrum Therapeutics by 61.4% in the 3rd quarter. State Street Corp now owns 1,680,229 shares of the company’s stock worth $5,998,000 after purchasing an additional 638,955 shares during the period. Assenagon Asset Management S.A. purchased a new position in Fulcrum Therapeutics during the second quarter worth approximately $3,084,000. Charles Schwab Investment Management Inc. grew its holdings in Fulcrum Therapeutics by 223.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 569,185 shares of the company’s stock valued at $2,032,000 after purchasing an additional 393,202 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Fulcrum Therapeutics in the third quarter valued at approximately $721,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.